Tom 10 (2024): Continuous Publishing
Artykuł redakcyjny
Opublikowany online: 2024-09-20
Ryzyko sercowo-naczyniowe u kobiet z cukrzycą typu 2 — czy nadal jest zagadką?
Diabetologia Praktyczna 2024;10:60-64.
Streszczenie
Brak
Referencje
- Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021; 397(10292): 2385–2438.
- Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34(1): 29–34.
- Kannel WB, McGee DL. Diabetes and Cardiovascular Disease. JAMA. 1979; 241(19): 2035–2038.
- Sarwar N, Gao P, Seshasai SR, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215–2222.
- Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018; 6(7): 538–546.
- Roche MM, Wang PP. Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. Diabetes Care. 2013; 36(9): 2582–2590.
- Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015; 3(2): 105–113.
- McAllister DA, Read SH, Kerssens J, et al. Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation. 2018; 138(24): 2774–2786.
- Wright AK, Kontopantelis E, Emsley R, et al. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort Study Assessing Sex Disparities. Circulation. 2019; 139(24): 2742–2753.
- Malmborg M, Schmiegelow MDS, Nørgaard CH, et al. Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men? Eur Heart J. 2020; 41(13): 1346–1353.
- Weerawickrama PK, Weerasinghe C, Fernando AS, et al. Prevalence of Cardiovascular Disease Risk Factors And Assessment of 10-Year Risk of Developing Cardiovascular Diseases in Premenopausal and Postmenopausal Women with Type 2 Diabetes: A Comparative Analysis. Clin Diabetol. 2024; 13(2): 93–100.
- Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017; 357: j2099.
- Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019; 62(10): 1761–1772.
- Wright AK, Kontopantelis E, Emsley R, et al. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort Study Assessing Sex Disparities. Circulation. 2019; 139(24): 2742–2753.
- Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016. Circulation. 2019; 139(8): 1025–1035.
- Vaccarino V, Rathore SS, Wenger NK, et al. National Registry of Myocardial Infarction Investigators. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005; 353(7): 671–682.
- Wenger NK. Clinical presentation of CAD and myocardial ischemia in women. J Nucl Cardiol. 2016; 23(5): 976–985.
- Gao Z, Chen Z, Sun A, et al. Gender differences in cardiovascular disease. Medicine in Novel Technology and Devices. 2019; 4: 100025.
- Rosano GMC, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015; 36(40): 2677–2680.
- Dennis JM, Henley WE, Weedon MN, et al. MASTERMIND Consortium. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. 2018; 41(9): 1844–1853.
- Zeitler P, Hirst K, Pyle L, et al. TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012; 366(24): 2247–2256.
- Anichini R, Cosimi S, Di Carlo A, et al. Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab Syndr Obes. 2013; 6: 123–129.
- Singh AK, Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes Metab Syndr. 2020; 14(3): 181–187.
- Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295(3): 306–313.
- Rosano GMC, Collins P. Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology. Fundam Clin Pharmacol. 2010; 24(6): 662–663.
- Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000; 355(9215): 1575–1581.
- Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992; 13(1): 28–32.
- Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002; 347(18): 1403–1411.
- Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002; 359(9302): 189–198.
